Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | MARS2 | Q96GW9 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 6/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19408174 | 0.81 | PRMT5 (0.40) | TDP1PRMT5SIRT2MARS2GRIN2B | |
| SCHEMBL9318815 | 0.81 | GAA (0.47) | PRMT5SIRT2MARS2 | |
| Hydrochloric Acid SCHEMBL19377908 | 0.80 | PRMT5 (0.39) | TDP1KDM4EPRMT5SIRT2MARS2 | |
| SCHEMBL17513504 | 0.79 | RAD52 (0.44) | TDP1KDM4EMEN1KMT2APRMT5 | |
| SCHEMBL9851422 | 0.79 | MARS2 (0.41) | KDM4EKMT2APRMT5SIRT2MARS2 | |
| SCHEMBL19378102 | 0.76 | CACNA1H (0.40) | TDP1KDM4EMEN1KMT2APRMT5 | |
| SCHEMBL10439327 | 0.76 | PARP1 (0.40) | KMT2APRMT5MARS2 | |
| SCHEMBL2299823 | 0.75 | PRMT5 (0.49) | KDM4EPRMT5SIRT2MARS2GRIN2B | |
| SCHEMBL23725578 | 0.74 | PRMT5 (0.44) | PRMT5SIRT2MARS2GRIN2B | |
| SCHEMBL6299123 | 0.71 | ALDH1A1 (0.44) | TDP1PRMT5SIRT2MARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131905-B1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3131905-B1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-28 | — | — | EP | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9738652-B2 | Spiro urea compounds as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738652-B2 | Spiro urea compounds as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738652-B2 | Spiro urea compounds as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-22 | — | — | US | disclosed |
| EP-3131905-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044172-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044172-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-02-16 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2651933-B1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2015158653-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015158653-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| WO-2012080449-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044172-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | REN, ZC3HAV1, SAV1 | TDP1 4556/4885KDM4E 2253/4885MEN1 4113/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | TDP1 3193/4885KDM4E 1258/4885MEN1 1913/4885 |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | TDP1 3193/4885KDM4E 1258/4885MEN1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.